A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
Article in ESMO Open (May 2023)
The most recent citing publications are shown below. View all 15 publications that cite this research output on Dimensions.
Article in ESMO Open (May 2023)
Article in Frontiers in Pharmacology (November 2022)
Article in Cell Communication and Signaling (April 2022)